Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M T Voso

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Bone Marrow Transplantation|May 9, 2000
Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT)M T Voso, S Martin, S Hohaus, et al.
Seminars in Oncology|May 13, 1998
Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancerS Hohaus, D Wallwiener, S Martin, et al.
British Journal of Haematology|June 20, 1998
The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recoveryS Martin-Murea, M T Voso, S Hohaus, et al.
Cancer Chemotherapy and Pharmacology|December 22, 1999
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancerS Hohaus, S Martin, A Schneeweiss, et al.
Haematologica|November 1, 1994
Salvage chemotherapy with pentostatin in prolymphocytic leukemiaL Pagano, E O Ortu-La Barbera, M T Voso, et al.
Cancers|October 23, 2019
Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment StrategiesN I Noguera, G Catalano, C Banella, et al.
Experimental Hematology|March 1, 1997
RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpressionC Rumi, S Rutella, L Teofili, et al.
Current Topics in Microbiology and Immunology|January 1, 1996
Function of PU.1 (Spi-1), C/EBP, and AML1 in early myelopoiesis: regulation of multiple myeloid CSF receptor promotersD E Zhang, S Hohaus, M T Voso, et al.
British Journal of Haematology|August 6, 2000
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphomaM T Voso, G Pantel, M Weis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 2007
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymesM T Voso, E Fabiani, F D'Alo', et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Bone Marrow Transplantation|May 9, 2000
Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT)M T Voso, S Martin, S Hohaus, et al.
Seminars in Oncology|May 13, 1998
Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancerS Hohaus, D Wallwiener, S Martin, et al.
British Journal of Haematology|June 20, 1998
The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recoveryS Martin-Murea, M T Voso, S Hohaus, et al.
Cancer Chemotherapy and Pharmacology|December 22, 1999
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancerS Hohaus, S Martin, A Schneeweiss, et al.
Haematologica|November 1, 1994
Salvage chemotherapy with pentostatin in prolymphocytic leukemiaL Pagano, E O Ortu-La Barbera, M T Voso, et al.
Cancers|October 23, 2019
Acute Promyelocytic Leukemia: Update on the Mechanisms of Leukemogenesis, Resistance and on Innovative Treatment StrategiesN I Noguera, G Catalano, C Banella, et al.
Experimental Hematology|March 1, 1997
RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpressionC Rumi, S Rutella, L Teofili, et al.
Current Topics in Microbiology and Immunology|January 1, 1996
Function of PU.1 (Spi-1), C/EBP, and AML1 in early myelopoiesis: regulation of multiple myeloid CSF receptor promotersD E Zhang, S Hohaus, M T Voso, et al.
British Journal of Haematology|August 6, 2000
In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphomaM T Voso, G Pantel, M Weis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 2007
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymesM T Voso, E Fabiani, F D'Alo', et al.
Pageof 6